Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer
Authors:
- Shohei HamadaSHShohei Hamada
- Hidenori IchiyasuHIHidenori Ichiyasu
- Tokunori IkedaTITokunori Ikeda
- Megumi InabaMIMegumi Inaba
- Kosuke KashiwabaraKKKosuke Kashiwabara
- Tomoki SadamatsuTSTomoki Sadamatsu
- Nahoko SatoNSNahoko Sato
- Kimitaka AkaikeKAKimitaka Akaike
- Hiroko OkabayashiHOHiroko Okabayashi
- Koichi SaruwatariKSKoichi Saruwatari
- Yusuke TomitaYTYusuke Tomita
- Sho SaekiSSSho Saeki
Open Access
- 2 April 2019
- journal article
- research article
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 19 (1) , 1-10
Abstract
Acute exacerbation of interstitial lung disease (AE-ILD) is the most serious complication in lung cancer patients with pre-existing ILD receiving chemotherapy. The role of vascular endothelial growth factor (VEGF) in pathogenesis of AE-ILD is conflicting. The influence of bevacizumab (Bev), a monoclonal antibody against VEGF, on lung cancer patients with pre-existing ILD remains unclear. We examined the effect of Bev on reducing AE-ILD risk in non-squamous non-small cell lung cancer (NSCLC) patients receiving chemotherapy. We analysed incidence of AE-ILD and outcomes of 48 patients with advanced non-squamous NSCLC with ILD who received first-line chemotherapy with (Bev group, n = 17) and without (non-Bev group, n = 31) Bev between July 2011 and July 2016. Gray’s test, which was competing risk analysis during the study period, was performed for both groups. The most common regimen used for first-line chemotherapy was the combination of carboplatin plus pemetrexed (PEM) in both groups. The incidences of chemotherapy-related AE-ILD 120 days after first-line chemotherapy initiation were significantly lower in the Bev than in the non-Bev groups (0% vs. 22.6%, p = 0.037, Gray’s test). However, there were no differences in development of progressive disease of lung cancer and other events as the competing risk factors of AE-ILD between the two groups. Only patients receiving PEM-containing regimens also showed a significant difference in the incidence of AE-ILD between the two groups (p = 0.044). The overall-cumulative incidence of AE-ILD during the first-line and subsequent chemotherapy was 29.2% (14 of the 48). The median progression-free survival was significantly longer in the Bev than in the non-Bev groups (8.0 vs. 4.3 months, p = 0.026). The addition of Bev to chemotherapy regimens may reduce the risk of chemotherapy-related AE-ILD in patients with lung cancer.Keywords
This publication has 38 references indexed in Scilit:
- Efficacy of Chemotherapy for Advanced Non-Small Cell Lung Cancer with Idiopathic Pulmonary FibrosisRespiration, 2012
- Lung Cancer and Interstitial Lung Diseases: A Systematic ReviewPulmonary Medicine, 2012
- The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumoniasLung Cancer, 2011
- MMP expression and abnormal lung permeability are important determinants of outcome in IPFEuropean Respiratory Journal, 2008
- Acute Exacerbations of Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerNew England Journal of Medicine, 2006
- Pathophysiological consequences of VEGF-induced vascular permeabilityNature, 2005
- Standardisation of the measurement of lung volumesEuropean Respiratory Journal, 2005
- Angiogenic cytokines in patients with idiopathic interstitial pneumoniaThorax, 2004
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskThe Annals of Statistics, 1988